Navigation Links
Wyeth Announces the Election of Robert M. Amen to Its Board of Directors
Date:9/27/2007

MADISON, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today the election of Robert M. Amen, 58, to the Company's Board of Directors, effective October 1, 2007. This election increases the number of Wyeth board members from 13 to 14.

Mr. Amen is Chairman and Chief Executive Officer of International Flavors & Fragrances Inc. (NYSE: IFF) in New York -- one of the world's leading creators of flavors and fragrances used in a wide variety of consumer products and packaged goods.

Prior to joining IFF, Mr. Amen served 26 years with International Paper Company, most recently as President, until retiring in March 2006. He currently is a member of the Advisory Board of the Deming Center at Columbia University in New York City, the Committee to Encourage Corporate Philanthropy and the Board of the Inner-City Scholarship Fund.

Mr. Amen has a bachelor's degree in economics from Boston College and a master's degree in business administration from Columbia University.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Wyeth Launches Vaccine for Pneumococcal Disease in India
2. Wyeth Embroiled in a Lawsuit over its Hormone Replacement Therapy
3. Wyeth Pharma Wins Law Suit
4. Verdict Against Wyeth Pharma in Prempro Case
5. FDA Approves Wyeths Oral Contraceptive Lybrel
6. PM announces a new health care order for India
7. Ramdoss Announces Introduction of RCH-II
8. Britain Announces Third Transfusion Related Mad Cow Case
9. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
10. Tibet Announces the Dalai Lama’s Tour of South Americ
11. NHS announces further Cost cutting Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ield University are in the hope of using stem cell... by creating embryonic stem cells // from the inne...he researchers have tried to regenerate the damage... make them divide into required cell, which has le...
...ry popular drink in Europe and more so in Germany....ave manufactured a healthy beer called karla //, w...nd also prevent cancer. The beer is made form her...oya extract, folic acid and vitamins. It is also w...
...ealed that a IQ level is directly linked to growth...s directly linked to the IQ level of the child, ac...rs. This study also reveals that the children who ... comparison to shorter children. If growth hormone...
... AIDS Day, the Vatican has condemned a culture of ...rted that the best way to prevent the spread // o...icted to marriage and intensifying the strength of...ternational day of action on HIV and AIDS, is comm...
Other Medicine News:
(Date:9/4/2008)...cian-Gynecologists States UFE Meets Level,A Eviden... Interventional,Radiology Treatment Is Safe, Effec...FAX, Va., Sept. 4 /PRNewswire-USNewswire/ -- The S...anization of nearly 4,500 doctors,scientists and ... health,care through minimally invasive treatment ...
(Date:9/4/2008)...t antiviral activity and favorable safety ..., Sept. 4 /- Idenix,Pharmac...al company engaged,in the discovery and developmen...her infectious diseases, today announced that it h... IDX899, a non-nucleoside reverse,transcriptase in...
(Date:9/3/2008)...swire-FirstCall/ -- Simcere,Pharmaceutical Group (...of,branded generic pharmaceuticals and manufacture... (also known as Endostar) in China,announced the ... At the request of the SFDA, Simcere initiated a P...ety and therapeutic efficacy of Endu, a modified,v...
(Date:9/3/2008)...Newswire/ -- Panacea Pharmaceuticals,Inc. today a...737 covering,antibodies against human aspartyl (as...human cancer biomarker and therapeutic target. The... the Massachusetts Institute of,Technology (MIT) a... patent,for development of human cancer diagnostic...
Breaking Medicine Technology:Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 1Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 2Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 3Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 4Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 5Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 6Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 7Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 8Patient Safety Authority Board of Directors Names Infection Advisory Panel 1034 9Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death Heart Attack and Stroke but Increases Risk of Heart Failure 245 1Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death Heart Attack and Stroke but Increases Risk of Heart Failure 245 2Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death Heart Attack and Stroke but Increases Risk of Heart Failure 245 3Takeda statement on ACTOS meta analysis published in the Journal of the American Medical Association 1027 1Takeda statement on ACTOS meta analysis published in the Journal of the American Medical Association 1027 2Other highlights in the September 11 JNCI 1024 1Other highlights in the September 11 JNCI 1024 2Other highlights in the September 11 JNCI 1024 3
CVC 223 is an assayed quality control material used for confirming the calibration and linearity of CO-Oximeter instrumentation.
...ol material used for monitoring the performance of...tation. It is for specific use on Bayer analyzers ...ions (280, 288, and 270) and the AVOX Systems CO-O... on the IRMA TRUpoint®. CC 527 is available i...
QC 623 is an assayed quality control material for blood gas and electrolyte instrumentation. It is available in four (4) levels for monitoring analyzer performance at varying points within the clinic
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens.
Medicine Products: